TECNOTREE
10.6.2022 13:47:07 CEST | Business Wire | Press release
Tecnotree, a Finland-based global provider of digital transformation solutions for Digital Service Providers (DSPs), today announced that it has been selected as ‘MongoDB Independent Software Vendor (ISV) Partner of the Year - Telco’ winner in the annual MongoDB World event at New York.
Padma Ravichander, CEO Tecnotree, said “We are proud to receive this award from MongoDB for helping our customers transition to new technologies and build digital ecosystems. Our technology platform allows customers to quickly deploy new services in response to market demand. Tecnotree’s digital BSS suite 5 provides end-to-end digital transformation for our enterprise customers, creating new efficiencies along the value chains. We are honoured to have this partnership with MongoDB. As we prepare for another exciting year ahead, we will continue to work closely with them to build custom-tailored solutions for our consumers.”
‘The MongoDB Partner of the Year Awards’ honour projects and people that thrive to help MongoDB telecom customers with their journey to the cloud. They celebrate the ground-breaking use of data to build compelling applications, modernize legacy ones, and the creativity of professionals expanding the limits of technology with MongoDB. This year partners were selected based on MongoDB end customer impact and influence.
Tecnotree was selected based on its unique set of offerings in the form of Cloud management, mobility and IoT, enterprise application development, software maintenance, and real-time offerings for enhanced customer experience, with their complete range of BSS Suite products and services. Tecnotree is addressing its goals towards building digital ecosystems by providing enterprises with a variety of solutions that help them with their digital transformation journey, using MongoDB as the underlying technology.
“At MongoDB, our partners are critical to our ability to care for our customers. The last two years have been a remarkably challenging time, with widespread changes affecting the entire world—and certainly the IT industry—like never before. However, this time has also brought customers and partners together to solve common problems,” said Alan Chhabra, Executive Vice President of Worldwide Partners, MongoDB. “At MongoDB, we’re committed to helping our customers evolve to this next stage of necessary innovation and are so grateful to all our partners who help make it happen. We’re cheering on this year's winners to carry on this competition’s legacy of honouring game-changing ideas, and I look forward to seeing the influence they make on the industry and the future.”
About Tecnotree
Tecnotree is the full-stack digital business management solution provider for digital service providers, with over 40 years of deep domain knowledge, proven delivery, and transformation capability across the globe. Our open-source technology-based agile products comprise the full range (order-to-cash) of business process and subscription management for telecom and DSPs with a pre-integrated B2B2X partner ecosystem across gaming, health, education, OTT, etc. Tecnotree products, platforms, and partners support emerging ecosystems of over 1 Billion subscribers across 70+ countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220610005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom